A sequence of human tumors for IDH1 or IDH2 mutations, or monoclonal antibodies against the most common IDH1 mutation (R132H), allows for immunohistochemical analysis of low-grade gliomas and GBMs. Here, IDH1 is linked to central nervous system cancer.